Trial Profile

A Phase 1 Study of ASP1002 in Participants With Metastatic or Locally Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASP 1002 (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
Focus Adverse reactions
Sponsors Astellas Pharma Global Development

Most Recent Events

10 Jun 2024 Status changed from active, no longer recruiting to recruiting.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
03 Apr 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com